Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.

Liu YJ, Zhang Q, Hu SY, Zhao FH.

BMC Cancer. 2016 Feb 26;16:164. doi: 10.1186/s12885-016-2207-3.

2.

Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N.

J Infect Dis. 2016 May 1;213(9):1444-54. doi: 10.1093/infdis/jiv753. Epub 2015 Dec 21.

PMID:
26690341
3.

Systematic review of model-based cervical screening evaluations.

Mendes D, Bains I, Vanni T, Jit M.

BMC Cancer. 2015 May 1;15:334. doi: 10.1186/s12885-015-1332-8. Review.

4.

Perception of human papillomavirus infection, cervical cancer and HPV vaccination in North Indian population.

Hussain S, Nasare V, Kumari M, Sharma S, Khan MA, Das BC, Bharadwaj M.

PLoS One. 2014 Nov 11;9(11):e112861. doi: 10.1371/journal.pone.0112861. eCollection 2014.

5.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

7.

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Turner HC, Baussano I, Garnett GP.

PLoS One. 2013 Sep 26;8(9):e75552. doi: 10.1371/journal.pone.0075552. eCollection 2013.

8.

Comparing cancer care, outcomes, and costs across health systems: charting the course.

Lipscomb J, Yabroff KR, Hornbrook MC, Gigli A, Francisci S, Krahn M, Gatta G, Trama A, Ritzwoller DP, Durand-Zaleski I, Salloum R, Chawla N, Angiolini C, Crocetti E, Giusti F, Guzzinati S, Mezzetti M, Miccinesi G, Mariotto A.

J Natl Cancer Inst Monogr. 2013;2013(46):124-30. doi: 10.1093/jncimonographs/lgt011. No abstract available.

9.

Modeling preventative strategies against human papillomavirus-related disease in developed countries.

Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ.

Vaccine. 2012 Nov 20;30 Suppl 5:F157-67. doi: 10.1016/j.vaccine.2012.06.091. Review.

10.

Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women.

Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O'Reilly SF, Kiviat NB, Koutsky LA.

Sex Transm Dis. 2012 Nov;39(11):848-56. doi: 10.1097/OLQ.0b013e3182641f1c. Erratum in: Sex Transm Dis. 2013 Nov;40(11):898.

11.

Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women.

Tsu V, Murray M, Franceschi S.

Br J Cancer. 2012 Oct 23;107(9):1445-50. doi: 10.1038/bjc.2012.404. Epub 2012 Sep 6. Review.

12.
13.

A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2013 Jan 1;132(1):198-207. doi: 10.1002/ijc.27608. Epub 2012 Jun 20.

14.
15.

Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.

Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR.

HIV Clin Trials. 2012 Jan-Feb;13(1):1-10. doi: 10.1310/hct1301-001.

16.

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.

van Rosmalen J, de Kok IM, van Ballegooijen M.

BJOG. 2012 May;119(6):699-709. doi: 10.1111/j.1471-0528.2011.03228.x. Epub 2012 Jan 18.

17.

The known unknowns of HPV natural history.

Gravitt PE.

J Clin Invest. 2011 Dec;121(12):4593-9. doi: 10.1172/JCI57149. Epub 2011 Dec 1. Review.

18.

Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities.

Goldie SJ, Daniels N.

J Natl Cancer Inst. 2011 Sep 21;103(18):1373-86. doi: 10.1093/jnci/djr303. Epub 2011 Sep 6.

19.

Human papillomavirus testing in the prevention of cervical cancer.

Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE.

J Natl Cancer Inst. 2011 Mar 2;103(5):368-83. doi: 10.1093/jnci/djq562. Epub 2011 Jan 31. Review.

20.

U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality.

Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG.

Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):591-9. doi: 10.1158/1055-9965.EPI-10-1183. Epub 2011 Jan 25.

Items per page

Supplemental Content

Write to the Help Desk